Zenas BioPharma, Inc.
ZBIO$259M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWALTHAM130 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7wMarket Overview
Stock performance and key metrics
ZBIO News
Catalyst Timeline
2 upcoming, 2 past
Phase 3Next
✓PositiveObexelimab Phase 3 Est. Readout
June 2026~ConfirmedObexelimab134
Primary completion for Obexelimab trial (NCT05786573) in Warm Autoimmune Hemolytic Anemia
Registrational Phase 3 INDIGO trial data announced and published in New England Journal of Medicine
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
Obexelimab
IgG4 Related Disease
Orelabrutinib
Multiple Sclerosis (MS) Primary Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obexelimab | Phase 3 | IgG4 Related Disease | - | - |
Orelabrutinib | Phase 3 | Multiple Sclerosis (MS) Primary Progressive | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply